Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$55.30 USD

55.30
7,657,067

+0.98 (1.80%)

Updated Nov 4, 2024 03:55 PM ET

After-Market: $55.46 +0.16 (0.29%) 4:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BMY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Bristol Myers Squibb Company falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 12,280 9,253 16,966 15,831 15,393
Receivables 10,921 9,886 9,369 8,501 7,685
Notes Receivable 0 0 0 0 0
Inventories 2,662 2,339 2,095 2,074 4,293
Other Current Assets 5,907 5,795 4,832 3,786 1,983
Total Current Assets 31,770 27,273 33,262 30,192 29,354
Net Property & Equipment 6,646 6,255 6,049 5,886 6,252
Investments & Advances 364 0 0 433 767
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 2,768 1,344 1,439 1,161 510
Intangibles 48,241 57,008 63,029 73,790 86,457
Deposits & Other Assets 5,370 4,940 5,535 7,019 6,604
Total Assets 95,159 96,820 109,314 118,481 129,944
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 3,259 3,040 2,949 2,713 2,445
Current Portion Long-Term Debt 3,119 4,264 4,948 2,340 3,346
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 15,884 14,586 13,971 14,027 12,513
Total Current Liabilities 22,262 21,890 21,868 19,080 18,304
Mortgages 0 0 0 0 0
Deferred Taxes/Income 338 2,166 4,501 5,407 6,454
Convertible Debt 0 0 0 0 0
Long-Term Debt 36,653 35,056 39,605 48,336 43,387
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 6,421 6,590 7,334 7,776 10,101
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 65,674 65,702 73,308 80,599 78,246
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 292 292 292 292 292
Capital Surplus 45,684 45,165 44,361 44,325 43,709
Retained Earnings 28,766 25,503 23,820 21,281 34,474
Other Equity -1,491 -1,224 -1,208 -1,779 -1,420
Treasury Stock 43,766 38,618 31,259 26,237 25,357
Total Shareholder's Equity 29,485 31,118 36,006 37,882 51,698
Total Liabilities & Shareholder's Equity 95,159 96,820 109,314 118,481 129,944
Total Common Equity 29,485 31,118 36,006 37,882 51,698
Shares Outstanding 2,034.70 2,126.10 2,219.60 2,262.60 2,228.00
Book Value Per Share 14.49 14.64 16.22 16.74 23.20

Fiscal Year End for Bristol Myers Squibb Company falls in the month of December.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents 8,094 6,653 9,670 12,280 7,685
Receivables 11,026 11,423 10,447 10,921 10,304
Notes Receivable 0 0 0 0 0
Inventories 3,332 3,077 2,985 2,662 2,436
Other Current Assets 5,623 5,737 5,567 5,907 7,207
Total Current Assets 28,075 26,890 28,669 31,770 27,632
Net Property & Equipment 6,903 6,845 6,750 6,646 6,481
Investments & Advances 324 357 367 364 325
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 3,609 3,323 2,723 2,768 1,514
Intangibles 48,715 51,160 54,498 48,241 50,097
Deposits & Other Assets 6,044 6,071 6,024 5,370 5,214
Total Assets 93,670 94,646 99,031 95,159 91,263
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 3,469 3,751 3,539 3,259 2,813
Current Portion Long-Term Debt 1,078 3,531 6,190 3,119 5,467
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 18,091 15,983 16,093 15,884 15,182
Total Current Liabilities 22,638 23,265 25,822 22,262 23,462
Mortgages 0 0 0 0 0
Deferred Taxes/Income 430 461 442 338 399
Convertible Debt 0 0 0 0 0
Long-Term Debt 48,674 48,858 49,487 36,653 32,137
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 4,728 6,732 6,421 6,203
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 76,470 77,577 82,483 65,674 62,201
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 292 292 292 292 292
Capital Surplus 45,896 45,766 45,655 45,684 44,849
Retained Earnings 16,097 16,103 15,640 28,766 28,218
Other Equity -1,410 -1,402 -1,342 -1,491 -1,222
Treasury Stock 43,675 43,690 43,697 43,766 43,075
Total Shareholder's Equity 17,200 17,069 16,548 29,485 29,062
Total Liabilities & Shareholder's Equity 93,670 94,646 99,031 95,159 91,263
Total Common Equity 17,200 17,069 16,548 29,485 29,062
Shares Outstanding 2,028.10 2,027.40 2,027.10 2,034.70 2,034.70
Book Value Per Share 8.48 8.42 8.16 14.49 14.28